PROTEUS Hormone Regimen in Prostate Cancer
A new hormone regimen for prostate cancer surgery patients moved from theory to Phase 3 evidence at ASCO 2026: perioperative apalutamide plus ADT in the PROTEUS trial improved pathologic response and cut metastasis or death risk versus hormone therapy alone around radical prostatectomy.
Contents10 sections
Key Takeaways
- PROTEUS (NCT03767244) randomized high-risk localized or locally advanced prostate cancer patients to perioperative apalutamide plus ADT versus placebo plus ADT with radical prostatectomy.
- Pathologic complete response or minimal residual disease was 8.9% with apalutamide versus 1.0% with ADT alone in sponsor disclosures.
- Risk of metastasis or death fell by 20% (HR 0.80) with the intensified perioperative regimen.
- Perioperative labeling is not automatic; teams should track supplemental filings and guideline updates separately from existing Erleada indications.
What hormone regimen did PROTEUS test around surgery?
PROTEUS is a randomized, double-blind, placebo-controlled Phase 3 study registered as NCT03767244 on ClinicalTrials.gov. It evaluates apalutamide plus androgen deprivation therapy given perioperatively—about six months before and after radical prostatectomy—against placebo plus ADT.
The population is newly diagnosed high-risk localized or locally advanced prostate cancer. That design directly tests whether intensifying hormone blockade around surgery changes pathologic and metastasis-free outcomes, not only PSA kinetics.
What efficacy signals matter for BD and medical strategy?
ASCO 2026 plenary disclosures reported dual primary endpoint success. Patients on apalutamide plus ADT were far more likely to reach pathologic complete response or minimal residual disease (8.9% vs 1.0%). Metastasis-free survival improved with a hazard ratio of 0.80 for metastasis or death.
Those absolute pathologic rates remain modest, so commercial models should not assume most surgical patients will convert to pCR. The strategic value is the randomized MFS benefit in a >2,000-patient perioperative setting—scale few neoadjuvant prostate programs achieve.
How does hormone therapy work in prostate cancer?
According to the National Cancer Institute hormone therapy fact sheet, androgen deprivation and androgen-receptor pathway blockade slow prostate cancer growth by lowering androgen levels or blocking androgen action.
Apalutamide is a next-generation androgen receptor pathway inhibitor already used in metastatic castration-sensitive and nonmetastatic castration-resistant disease. PROTEUS asks whether moving that intensity into the perioperative window improves cure-oriented surgery outcomes.
What should regulatory and market-access teams watch?
Key questions are proprietary filing timing for a perioperative supplemental indication, acceptance of pathologic response as a supportive endpoint, and how five-year MFS curves hold with longer follow-up. Adverse-event differentials—especially rash—were flagged as more common with apalutamide in public summaries.
Payers will weigh absolute MFS gains against toxicity, treatment duration around surgery, and whether intensified ADT alone already captures much of the benefit. Competitors with other ARPIs need to decide whether to run head-to-head perioperative programs or concede this niche.
How should surgical oncology pathways adapt?
- Identify high-risk patients who meet PROTEUS-like entry criteria before prostatectomy staging conferences.
- Coordinate medical oncology start dates so neoadjuvant dosing does not delay operable windows without cause.
- Track adjuvant continuation adherence after surgery—perioperative benefit assumes both halves of the regimen.
- Separate investigational perioperative use from currently labeled ARPI settings in counseling materials.
What remains unproven?
PROTEUS does not prove that every localized prostate cancer patient needs intensified perioperative therapy, nor that apalutamide beats every alternative ARPI in this setting. Overall survival maturity, quality-of-life trade-offs, and label expansion remain open. Vague earlier references to unnamed “new hormone regimens” without NCT identifiers are replaced here by the sourced PROTEUS program.
Head-to-head perioperative comparisons against other androgen receptor pathway inhibitors were not the PROTEUS design. Until regulators act and guidelines update, surgical pathways should treat the regimen as evidence-backed investigational practice rather than a default order set for all high-risk prostatectomy candidates.
Related NovaPharma coverage
- Prostate cancer disease hub
- Breast Cancer Statistics Worldwide: What the Data Shows
- Akeso and Summit Drug Shows Promise in Lung Cancer Trial
Frequently Asked Questions
What new hormone regimen was studied around prostate cancer surgery?
The Phase 3 PROTEUS trial (NCT03767244) tested perioperative apalutamide plus androgen deprivation therapy (ADT) given for six months before and after radical prostatectomy versus placebo plus ADT in high-risk localized or locally advanced prostate cancer.
What were the key PROTEUS efficacy findings?
Sponsor and investigator disclosures around ASCO 2026 reported that apalutamide plus ADT increased pathologic complete response or minimal residual disease to 8.9% versus 1.0% with ADT alone and reduced the risk of metastasis or death by 20% (HR 0.80).
Is perioperative apalutamide FDA-approved for this surgery setting?
Apalutamide (Erleada) is FDA-approved in other prostate cancer settings, but the perioperative radical-prostatectomy use studied in PROTEUS is investigational until any supplemental label change is approved. Confirm current labeling on Drugs@FDA.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
